Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

NorwayBack to Norway

Clinical trials in Drammen – page 5

70 clinical trials in Drammen, Norway across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Drammen at a glance
70
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

70 trials in Drammen

Open in trial search

Non-small cell lung cancer

Not recruiting

Study for Patients with Advanced Non-Small Cell Lung Cancer Worsened by Osimertinib Treatment, Using Selumetinib and Drug Combination

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Breast cancer

Not recruiting

Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

EGFR gene mutation+1

Not recruiting

Study of Osimertinib for Patients with EGFR-Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:Vestre Viken HF

Perioperative analgesia

Not recruiting

Study on the Emotional Effects of Morphine, Oxycodone, and Fentanyl Before Surgery in Healthy or Mildly Ill Patients

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Fentanyl
  • Sponsor:Vestre Viken HF

Non-small cell lung cancer+2

Not recruiting

Study of Niraparib and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

K-ras gene mutation+2

Not recruiting

Study on Sotorasib for Patients with Advanced KRAS G12C-Mutated Non-Small Cell Lung Cancer and Comorbidities

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Sotorasib
  • Sponsor:Vestre Viken HF

Colorectal cancer+6

Not recruiting

Study of INCB099280 and Ipilimumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:INCB099280
  • Sponsor:Incyte Corp.

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Camizestrant and Palbociclib with Anastrozole and Palbociclib for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

Amyotrophic lateral sclerosis

Not recruiting

Study of utreloxastat (PTC857) in adults with Amyotrophic Lateral Sclerosis (ALS) to evaluate its effectiveness in slowing disease progression

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Utreloxastat
  • Sponsor:PTC Therapeutics Inc.

Rheumatoid arthritis

Not recruiting

Study on Monitoring Adalimumab for Maintaining Disease Control in Adults with Rheumatoid Arthritis

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Adalimumab
  • Sponsor:Diakonhjemmet Sykehus AS

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Multiple sclerosis

Not recruiting

Study on the Safety of Tenofovir Alafenamide and Natalizumab for People with Multiple Sclerosis

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Natalizumab
  • Sponsor:Helse Bergen HF

Other cities in Norway

The busiest research cities in the country

All 54 cities in Norway

Clinical research in Drammen

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on various cancer types, including pancreatic ductal cancer, small-cell lung cancer, and advanced melanoma. Studies evaluate new combination therapies and treatment approaches.

  • Triple Negative Breast Cancer
  • Non-small Cell Lung Cancer
  • Colon Cancer Treatment

Research emphasizes improving survival rates and treatment efficacy through targeted therapies and immunotherapy combinations.

02 Cardiovascular Studies

Comprehensive research into cardiovascular diseases and preventive treatments. Trials explore new approaches for stroke prevention and management of heart conditions.

  • Atrial Fibrillation Management
  • Stroke Prevention
  • Atherosclerotic Disease

Focus on developing innovative antiplatelet therapies and investigating cardiovascular safety in various patient populations.

03 Chronic Disease Management

Studies addressing chronic conditions including Multiple Sclerosis, Crohn's Disease, and Rheumatoid Arthritis. Trials evaluate new therapeutic approaches and drug combinations.

  • COPD Treatment
  • Inflammatory Conditions
  • Metabolic Disorders

Research aims to improve disease control and patient outcomes through innovative treatment strategies.

Back to NorwayAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.